Menu Search
Equities

Exact Sciences Corp

EXAS:NAQ

Exact Sciences Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)53.05
  • Today's Change-0.02 / -0.04%
  • Shares traded2.58m
  • 1 Year change-18.56%
  • Beta1.2333
Data delayed at least 15 minutes, as of Nov 21 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy12
Outperform10
Hold3
Sell0
Strong Sell0

Share price forecast in USD

The 22 analysts offering 12 month price targets for Exact Sciences Corp have a median target of 70.00, with a high estimate of 89.21 and a low estimate of 60.00. The median estimate represents a 31.90% increase from the last price of 53.07.
High68.1%89.21
Med31.9%70.00
Low13.1%60.00

Earnings history & estimates in USD

On Nov 05, 2024, Exact Sciences Corp reported 3rd quarter 2024 losses of -0.21 per share. This result was in line with the consensus of the 14 analysts following the company and under-performed last year's 3rd quarter results by -0.21.
The next earnings announcement is expected on Feb 19, 2025.
Average growth rate-56.85%
Exact Sciences Corp reported annual 2023 losses of -1.13 per share on Feb 21, 2024.
Average growth rate-168.06%
More ▼

Revenue history & estimates in USD

Exact Sciences Corporation had 3rd quarter 2024 revenues of 708.66m. This missed the 717.67m consensus estimate of the 23 analysts following the company. This was 17.63% above the prior year's 3rd quarter results.
Average growth rate+3.13%
Exact Sciences Corporation had revenues for the full year 2023 of 2.50bn. This was 19.93% above the prior year's results.
Average growth rate+31.64%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.